- Home
- PHVS vs CGEM Comparison
PHVS vs CGEM Comparison
Compare PHVS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CGEM
- Stock Information
- Founded
- PHVS 2015
- CGEM 2016
- Country
- PHVS Switzerland
- CGEM United States
- Employees
- PHVS N/A
- CGEM N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- CGEM Health Care
- Exchange
- PHVS Nasdaq
- CGEM Nasdaq
- Market Cap
- PHVS 980.9M
- CGEM 530.0M
- IPO Year
- PHVS 2021
- CGEM 2021
- Fundamental
- Price
- PHVS $24.42
- CGEM $7.81
- Analyst Decision
- PHVS Buy
- CGEM Strong Buy
- Analyst Count
- PHVS 6
- CGEM 6
- Target Price
- PHVS $37.17
- CGEM $28.17
- AVG Volume (30 Days)
- PHVS 33.8K
- CGEM 360.3K
- Earning Date
- PHVS 08-13-2025
- CGEM 08-07-2025
- Dividend Yield
- PHVS N/A
- CGEM N/A
- EPS Growth
- PHVS N/A
- CGEM N/A
- EPS
- PHVS N/A
- CGEM N/A
- Revenue
- PHVS N/A
- CGEM N/A
- Revenue This Year
- PHVS N/A
- CGEM N/A
- Revenue Next Year
- PHVS N/A
- CGEM N/A
- P/E Ratio
- PHVS N/A
- CGEM N/A
- Revenue Growth
- PHVS N/A
- CGEM N/A
- 52 Week Low
- PHVS $11.51
- CGEM $6.85
- 52 Week High
- PHVS $25.76
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- PHVS 73.80
- CGEM 45.96
- Support Level
- PHVS $17.63
- CGEM $7.29
- Resistance Level
- PHVS $25.76
- CGEM $7.94
- Average True Range (ATR)
- PHVS 1.51
- CGEM 0.39
- MACD
- PHVS 0.69
- CGEM -0.01
- Stochastic Oscillator
- PHVS 82.19
- CGEM 61.01
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.